

Protalix BioTherapeutics, Inc.  
Form 8-K  
April 12, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): April 12, 2017**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**



**Item 5.07. Submission of Matters to a Vote of Security Holders**

The 2017 Annual Meeting of Stockholders of Protalix BioTherapeutics, Inc. (the “Company”) was held on April 12, 2017.

Set forth below, with respect to each such matter, are the number of votes cast for or against or withheld, as applicable, the number of abstentions and the number of broker non-votes.

(1) Election of Directors

	<b><u>For</u></b>	<b><u>Withheld</u></b>	<b><u>Broker Non-Votes</u></b>
Shlomo Yanai	35,190,098	6,120,657	24,013,342
Moshe Manor	34,675,377	6,635,378	24,013,342
Amos Bar Shalev	34,181,428	7,129,327	24,013,342
Zeev Bronfeld	35,555,532	5,755,223	24,013,342
Yodfat Harel Buchris	34,186,675	7,124,080	24,013,342
Aharon Schwartz, Ph.D.	34,233,859	7,076,896	24,013,342

(2) Approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers

	<b><u>For</u></b>	<b><u>Against</u></b>	<b><u>Abstain</u></b>	<b><u>Broker Non-Votes</u></b>
	33,876,405	6,920,511	365,044	24,162,137

(3) Approval, in accordance with Section 713(a) of the NYSE MKT Company Guide, the potential issuance of shares representing in excess of 19.9% of the Company’s pre-transaction total shares of common stock outstanding that may result from the conversion of, or payment of accrued interest on, the Company’s outstanding Convertible Notes

	<b><u>For</u></b>	<b><u>Against</u></b>	<b><u>Abstain</u></b>	<b><u>Broker Non-Votes</u></b>
	33,706,193	7,475,010	129,552	24,013,342

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

(4) Approval of an amendment to the Company's Certificate of Incorporation, as amended, to increase the number of shares of the Company's common stock, par value \$0.001 per share, authorized for issuance from 250,000,000 to 300,000,000

	<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker</u> <u>Non-Votes</u>
	33,355,376	7,831,222	124,157	24,013,342

(5) Ratification of the appointment of Kesselman & Kesselman

	<u>For</u>	<u>Against</u>	<u>Abstain</u>
	64,109,289	1,099,302	115,506

**Item 8.01. Other Events**

Reference is made to Item 5.07. As a result of the approval by the Company's stockholders of proposal 3 described above, for purposes of the Company's 7.5% convertible notes, April 12, 2017 is the Capped Combination Settlement Release Date as described in the Indenture dated as of December 7, 2016, between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS, INC.**

Date: April 12, 2017 By: /s/ Yossi Maimon  
Name: Yossi Maimon  
Title: Vice President and  
Chief Financial Officer